Form 8.3 -Strongbridge Biopharma Plc
24 Junio 2021 - 8:22AM
UK Regulatory
TIDM0A8E
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) State Street Global Advisors &
Affiliates
------------------------------------ ------------------------------
Company dealt in Strongbridge Biopharma plc
------------------------------------ ------------------------------
Class of relevant security to $0.01 ordinary shares
which
the dealings being disclosed relate
(Note 2)
------------------------------------ ------------------------------
Date of dealing 23rd June 2021
------------------------------------ ------------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant security dealt in (Note 3)
Long Short
--------------------------- ----------------- -----------
Number (%) Number (%)
--------------------------- ------- -------- ------ ---
(1) Relevant securities 743,750 1.09823%
--------------------------- ------- -------- ------ ---
(2) Derivatives (other
than options) N/A
--------------------------- ------- -------- ------ ---
(3) Options and agreements
to
purchase/sell N/A
--------------------------- ------- -------- ------ ---
Total 743,750 1.09823%
--------------------------- ------- -------- ------ ---
(b) Interests and short positions in relevant securities of the
company, other than the class dealt in (Note 3)
Class of relevant security: Long Short
--------------------------- ----------- -----------
Number (%) Number (%)
--------------------------- ------ --- ------ ---
(1) Relevant securities N/A
--------------------------- ------ --- ------ ---
(2) Derivatives (other N/A
than options)
--------------------------- ------ --- ------ ---
(3) Options and agreements N/A
to purchase/sell
--------------------------- ------ --- ------ ---
Total N/A
--------------------------- ------ --- ------ ---
3. DEALINGS (Note 4)
(a) Purchases and sales
Price per unit (Note
Purchase/sale Number of relevant securities 5)
-------------- ----------------------------- --------------------
Sale 570 2.80
-------------- ----------------------------- --------------------
(b) Derivatives transactions (other than options
transactions)
Product name, Nature of transaction Number of relevant securities Price per
e.g. CFD (Note 6) (Note 7) unit
(Note 5)
------------- --------------------- ----------------------------- ---------
N/A
------------- --------------------- ----------------------------- ---------
(c) Options transactions in respect of existing relevant
securities
(i) Writing, selling, purchasing or varying
Product name, Writing, Number of Exercise Type, e.g. Expiry Option money
e.g. call selling, securities to price American, date paid/received
option purchasing which European per unit
varying etc. the option relates etc. (Note 5)
(Note 7)
------------- ------------- ------------------- -------- ---------- ------ --------------
N/A
------------- ------------- ------------------- -------- ---------- ------ --------------
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 5)
----------------- -------------------- ------------------
N/A
----------------- -------------------- ------------------
(d) Other dealings (including transactions in respect of new
securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable) (Note
5)
--------------------- ------- ----------------------
N/A
--------------------- ------- ----------------------
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding between
the person disclosing and any other person relating to the voting
rights of any relevant securities under any option referred to
on this form or relating to the voting rights or future acquisition
or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be
stated.
--------------------------------------------------------------------
N/A
--------------------------------------------------------------------
Is a Supplemental Form 8 attached?
(Note 9) NO
-------------------------------------------- --------------
Date of disclosure 24th June 2021
-------------------------------------------- --------------
Contact name Lionel Colaco
-------------------------------------------- --------------
Telephone number 020 33956098
-------------------------------------------- --------------
If a connected EFM, name of offeree/offeror N/A
with which connected
-------------------------------------------- --------------
If a connected EFM, state nature N/A
of connection (Note 10)
-------------------------------------------- --------------
(END) Dow Jones Newswires
June 24, 2021 09:22 ET (13:22 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Xeris Biopharma (LSE:0A8E)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Xeris Biopharma (LSE:0A8E)
Gráfica de Acción Histórica
De May 2023 a May 2024
